Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.43 |
| ▸ | MTOR | P42345 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18708528 | 0.82 | HRH4 (0.45) | KMT2AMEN1CYP1A2CRHBPCRHR2 | |
| SCHEMBL23599609 | 0.81 | SMN1; SMN2 (0.44) | KMT2AMEN1CYP1A2CRHBPCRHR2 | |
| SCHEMBL15582906 | 0.79 | KMT2A (0.42) | KMT2AMEN1POLBCYP1A2CYP2D6 | |
| SCHEMBL24799739 | 0.78 | CYP11B1 (0.52) | KMT2AMEN1POLBCYP1A2PIK3CA | |
| SCHEMBL2640550 | 0.78 | HRH4 (0.54) | — | |
| SCHEMBL6014714 | 0.78 | HTR2C (0.64) | KMT2AMEN1CYP1A2HTT | |
| SCHEMBL3089415 | 0.78 | KMT2A (0.64) | KMT2AMEN1POLBCYP1A2CYP2D6 | |
| SCHEMBL12186838 | 0.78 | KMT2A (0.41) | KMT2AMEN1POLBCYP1A2CYP2D6 | |
| SCHEMBL9885000 | 0.78 | KMT2A (0.53) | KMT2AMEN1POLBCYP1A2MAPT | |
| SCHEMBL5524143 | 0.78 | ALDH1A1 (0.44) | KMT2AMEN1POLBCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3613743-A1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | Intellikine, LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-2240451-B1 | Isoquinolinone derivatives substituted with a purine useful as PI3K inhibitors | INTELLIKINE LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8969335-B2 | Benzonitrile derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2588473-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013034238-A1 | BENZONITRILE DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| CN-101472903-A | Pyrazine derivatives with extended conjugation and uses thereof | MALLINCKRODT INC (US) | 2009-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KMT2A 796/4885MEN1 1450/4885POLB 1468/4885 |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | KMT2A 3442/4885MEN1 4073/4885POLB 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.